Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifina
- Development stage
- Unknown
- Lead developer
- Morishita
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifina is a probiotic nutritional supplement originally developed by the Japanese company Morishita Jintan and distributed in China through a partnership with Sinopharm Xingsha Pharmaceuticals (Xiamen). The formulation contains a combination of prebiotics (oligosaccharides) and probiotic strains, specifically *Bifidobacterium longum* BB536, *Lactobacillus acidophilus*, and *Lactobacillus gasseri*. A distinguishing feature of the product is Morishita Jintan's proprietary 'seamless capsule' technology, which utilizes a triple-layer enteric coating to protect the live bacteria from gastric acid, ensuring their viable delivery to the intestines. Bifina is indicated for the management of gut microbiota imbalance and the support of general gastrointestinal and digestive health.
- Brand names
- BifinaHealth Aid Bifina
- Other names
- Bifina probioticsprobiotic supplement
Beyond the preview
Go deeper on Bifina.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifina.